NCT07736885 Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
| NCT ID | NCT07736885 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
| Condition | Post-Stroke Cognitive Impairment (PSCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-08-15 |
| Primary Completion | 2027-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2026-08-15 with a primary completion date of 2027-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke. Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms. Who can participate: Adults aged \[35-80\] who have had an ischemic stroke and now have mild to moderate cognitive impairment. What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment. Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain. Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.
Eligibility Criteria
Inclusion Criteria: 1. Aged 35-80 years; 2. Stroke duration within 2 weeks to 6 months post-onset; 3. Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score \< 26; 4. Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.); 5. No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study; 6. Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form. Exclusion Criteria: 1. Unstable vital signs or life-threatening comorbidities; 2. Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.); 3. History of epilepsy or epileptic seizures; 4. Pregnant or lactating women; 5. Concurrent use of other medications affecting cognitive function; 6. Allergy to the study intervention device or history of serious adverse reactions; 7. Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.); 8. Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07736885 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 80 Years, studying Post-Stroke Cognitive Impairment (PSCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07736885 currently recruiting?
Yes, NCT07736885 is actively recruiting participants. Contact the research team at Gaoliang202605@163.com for enrollment information.
Where is the NCT07736885 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07736885 clinical trial?
NCT07736885 is sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.